BAT Subsidiary WITCO: Vuse Has Strong Positive Impact on Revenue

Regulations by 2FIRSTS.ai
Apr.24.2024
BAT Subsidiary WITCO: Vuse Has Strong Positive Impact on Revenue
WITCO CEO Raoul Glynn announced at a press conference that Vuse e-cigarettes will positively impact company revenue.

According to a report by Newsday on April 24th, Raoul Glynn, CEO of West Indies Tobacco Company Limited (WITCO), announced at a press conference held at the Queen's Hall in Spain on April 23rd that the e-cigarette brand Vuse will have a strong and positive impact on the company's revenue.

 

The quality of Vuse products surpasses that of other brands on the market, with attractive prices and a strong profit structure. Witco's advantage lies in its distribution and ability to obtain the necessary products, which is what we value.

 

Greene stated that approximately 12% of consumers in the market are using e-cigarette products. "We anticipated changes in the market and observed e-cigarettes growing in a way that does not decrease tobacco sales."

 

Last week, the company revealed that as of December 31, 2023, its annual revenue had increased by 5.9% compared to the previous year. The company's financial director, Johan Grosberg, stated that despite taking many measures to improve operational efficiency last year, increased costs of raw materials, packaging, and labor led to an increase in sales costs. However, they were able to benefit from reduced expenses.

 

The brand support expenses align with our marketing plan, allowing us to trim slightly and execute the plan more effectively. Additionally, as part of a large group, we benefit from some restructuring taking place outside of the group.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity
Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity
Smoore International announced that the U.S. FDA has accepted the Abbreviated New Drug Application (ANDA) for its Breo® Ellipta® 100/25 generic drug, submitted by its wholly-owned subsidiary, Transpire Bio. Transpire Bio stated that if approved, it is expected to receive 180 days of market exclusivity. In the United States, Breo® Ellipta® is already approved for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD).
Sep.25 by 2FIRSTS.ai
Company | Bloomberg: JTI Bets on Value Cigarettes Against the Tide, While Steadily Expanding Heated Tobacco Globally
Company | Bloomberg: JTI Bets on Value Cigarettes Against the Tide, While Steadily Expanding Heated Tobacco Globally
Bloomberg reports that Japan Tobacco International (JTI) is pursuing a strategy that contrasts with peers such as Philip Morris International (PMI) and British American Tobacco (BAT). While global tobacco majors push “smoke-free” transitions, JTI continues to cultivate combustible cigarettes—particularly value brands in the United States—while advancing the global rollout of its heated-tobacco brand Ploom. JTI forecasts that value-priced cigarettes will exceed a 40% share of the U.S. market by 2
Sep.28 by 2FIRSTS.ai
British American Tobacco to Open glo™ Ginza Flagship Store in Tokyo on October 18
British American Tobacco to Open glo™ Ginza Flagship Store in Tokyo on October 18
BAT Japan to open two-storey glo™ Ginza flagship on Oct 18, 2025; sales + members’ lounge, promos; near IQOS.
Oct.11 by 2FIRSTS.ai
Dagestan Proposes Pilot Ban on E-Cigarette Sales, Submits Request to State Duma
Dagestan Proposes Pilot Ban on E-Cigarette Sales, Submits Request to State Duma
The head of Russia’s Republic of Dagestan has proposed a region-wide ban on the retail sale of e-cigarettes and has written to the State Duma seeking to designate Dagestan as a pilot region for a comprehensive e-cigarette sales ban.
Oct.21 by 2FIRSTS.ai
Bangladesh Tobacco Control Group Urges Reversal of Philip Morris Nicotine Pouch Factory Approval
Bangladesh Tobacco Control Group Urges Reversal of Philip Morris Nicotine Pouch Factory Approval
Advocates say the economic authority’s decision contradicts national health goals and violates a Supreme Court directive banning new tobacco ventures.
Oct.27 by 2FIRSTS.ai
Product | Three Power Levels + “2+10” Setup: ELFBAR JoinOne Series Launches in UK Retail
Product | Three Power Levels + “2+10” Setup: ELFBAR JoinOne Series Launches in UK Retail
ELFBAR rolls out the JoinOne15 Classic prefilled replaceable-pod kit, now listed across multiple UK e-commerce channels (some pages marked “coming soon”). The device uses a “2 ml prefilled pod + 10 ml refill container (‘2+10’)” system, supports three power levels, and claims up to 15,000 puffs in combined use. The kit is priced at £12.99, with matching “2+10” refill pods at £7.99.
Nov.03 by 2FIRSTS.ai